Clinical Trials Logo

Opioid-Related Disorders clinical trials

View clinical trials related to Opioid-Related Disorders.

Filter by:

NCT ID: NCT04737603 Not yet recruiting - Opioid-use Disorder Clinical Trials

Feasibility of Pediatric Emergency Department-Initiated Treatment for Adolescents With Opioid Use Disorder

PEDsTREATOUD
Start date: July 30, 2024
Phase: Phase 2
Study type: Interventional

ED-initiated buprenorphine with brief intervention and facilitated referral to treatment has been shown to be highly successful in increasing treatment engagement rates and reducing opioid use among adults. It is unknown whether this intervention is similarly effective for adolescents with OUD. To rigorously examine this important clinical research question, it is first necessary to optimize this intervention for the adolescent population. In this R34 proposal, we will use the Assessment-Decision-Administration-Production-Topic Experts-Integration-Training-Testing (ADAPT-ITT) framework-a systematic method for intervention adaptation- to adapt (Aim 1) and test the feasibility (Aim 2) of a treatment strategy for adolescents that has been shown to effectively link adults with OUD to ongoing addiction treatment.

NCT ID: NCT04691167 Not yet recruiting - Clinical trials for Substance Use Disorders

the Role of Repetitive Trans Cranial-magnetic Stimulation in Craving Reduction Among Opioid Use Disorder Patients

Start date: June 2022
Phase: N/A
Study type: Interventional

Repetitive Trans-cranial Magnetic Stimulation (rTMS) is a relatively safe and non-invasive method to modulate neuronal activity; rTMS uses alternating magnetic fields in a certain frequency to induce an electric current in the underlying brain tissue. Administering high frequency rTMS to the left dorsolateral prefrontal cortex is possible to increase brain activity in the stimulated area and to change brain activity in associated regions that are part of the same neural circuit which may reduce craving.

NCT ID: NCT04454411 Not yet recruiting - Opioid Dependence Clinical Trials

Brain Mechanisms of Pharmacotherapy in Opioid Use Disorder

Start date: February 1, 2025
Phase: Phase 2
Study type: Interventional

This study will investigate the mechanisms of cognitive-behavioral response to medications used for relapse prevention in opioid use disorder (opioid addiction, OUD), through investigation of the neural circuits underlying key cognition functions. The study will use previously validated cognitive probes, functional Magnetic Resonance Imaging (fMRI), and novel extended-release injectable preparations of opioid partial agonist buprenorphine and antagonist naltrexone, in OUD patients to explain the individual heterogeneity of OUD treatment response.

NCT ID: NCT04231708 Not yet recruiting - Opioid Use Disorder Clinical Trials

Effects of Pharmacological Stress and rTMS on Executive Function in Opioid Use Disorder

Start date: October 2024
Phase: Phase 2
Study type: Interventional

This preliminary study is designed to evaluate mechanisms by which excitatory dorsolateral prefrontal cortex (dlPFC) repetitive transcranial magnetic stimulation (rTMS) (vs. sham) and pharmacological stress (vs. placebo) alter behavior in non-treatment seeking individuals with opioid use disorder (OUD). Specific Aims are to (1) Evaluate how stress impacts domains of behavior including (1a) executive function and (1b) opioid-seeking behavior; and (2) Determine whether rTMS stimulation attenuates (2a) executive dysfunction, (2b) stress-reactivity, and (2c) opioid-seeking in individuals with OUD not receiving treatment.

NCT ID: NCT04228250 Not yet recruiting - Chronic Pain Clinical Trials

Overlapping Buprenorphine Initiation (in Opioid Physical Dependence)

Start date: January 2020
Phase: Phase 4
Study type: Interventional

This clinical trial aims to assess the tolerability and effectiveness of overlapping buprenorphine initiation and full agonist opioid discontinuation among patients on high-dose long-term full agonist opioid therapy who have opioid physical dependence.

NCT ID: NCT03813095 Not yet recruiting - Opioid Dependence Clinical Trials

Exploratory Dose Ranging Study Assessing APH-1501 for the Treatment of Opioid Addiction

Start date: October 2023
Phase: Phase 2
Study type: Interventional

The purpose of this study is determine the safety, efficacy and tolerability of a novel drug APH-1501 as a pharmacotherapy for Opioid Dependence. The investigators will evaluate the safety of escalating doses APH-1501.

NCT ID: NCT03804619 Not yet recruiting - Depression Clinical Trials

Accelerated Intermittent Theta-Burst Stimulation for Opiate Use Disorder

Start date: June 1, 2024
Phase: N/A
Study type: Interventional

This study aims to examine whether multiple spaced sessions of intermittent theta-burst transcranial magnetic stimulation (iTBS) induce anti-depressant responses and reduce opiate cravings in adults with opiate use disorder (OUD). Additionally, we hope to identify whether the effectiveness of iTBS is related to changes in functional connectivity between particular brain areas.

NCT ID: NCT03656120 Not yet recruiting - Opioid Dependence Clinical Trials

A Study of Thienorphine Hydrochloride Tablets in Relapse Prevention Treatment of Opioid Dependence

Start date: August 31, 2018
Phase: Phase 2
Study type: Interventional

Opioid addiction is common worldwide. Thienorphine hydrochloride is a newly partial opioid receptor agonist drugs. It`s affinity with opioid receptors was much higher than opioids, which could effectively prevents opioid dependence by stop opioids competition for opioid receptors and causing opioid dependence. The aim of this research was to determine whether thienorphine hydrochloride would reduce opioid use and better preventing relapse among opioid addicts.

NCT ID: NCT03595293 Not yet recruiting - Clinical trials for Alcohol Use Disorder

fNIRs-based Neurofeedback to Reduce Relapse in pOUD/AUD

Start date: January 1, 2026
Phase: N/A
Study type: Interventional

This study will examine the impact of functional near-infrared spectroscopy-based neurofeedback to a region within the brain's prefrontal cortex involved with self-regulation of resisting craving in alcohol use and prescription opioid use disorder patients. Participants will be asked to complete two cue reactivity tasks, six sessions of neurofeedback training as well as craving visual analog scales and self-efficacy questionnaires throughout a two-week period of their time in residential treatment at the Caron Treatment Center. They will be followed for 90 days after treatment completion at Caron to assess the impact neurofeedback had on their ability to remain sober once patients are living back in the "real world".

NCT ID: NCT03394911 Not yet recruiting - Opioid Use Clinical Trials

Healthy Adult Male Facial Skin Surface Lipid Pheromone p.o. to Treat Opioid Addiction

Start date: December 31, 2020
Phase: Phase 3
Study type: Interventional

Healthy adult human male facial skin surface lipid liquid pheromone given by mouth to opioid addicts cures them without any withdrawal symptoms whatsoever 250mg on chewing gum vehicle by mouth. Elevated mood eventually becomes accommodated after a few weeks. The pheromone contains volatile airborne sub-pheromones which cause aversive behavior (distrust, superstition, suspicion, arrogance, astonishment/stupidity, jealousy). Artificial jealousy can be avoided by patient isolation for 40 days until the pheromone "taste" wears off the saliva. The pheromone provided is odorless, colorless, and tasteless to the conscious brain.